Shenwei Pharmaceutical Group Co., Ltd.

Shenwei Pharmaceutical Group Co., Ltd. is a large-scale comprehensive enterprise group whose main business is modern traditional Chinese medicine. Its main business covers the upstream, midstream and downstream industrial chains such as the cultivation of traditional Chinese medicine, scientific research, extraction, production and marketing of traditional Chinese medicine. It is a professional manufacturer of modern traditional Chinese medicine injections, soft capsules and granules. Sunway Pharmaceutical Group Co., Ltd. is one of the top five companies in China's traditional Chinese medicine industry and the largest modern traditional Chinese medicine company in terms of market capitalization on the main board of the Hong Kong Stock Exchange. The company's more than ten main products, including Xinnaoqing Soft Capsules, Huoxiang Zhengqi Soft Capsules, Liyan Jiedu Granules, Shujin Tongluo Granules, Synovitis Granules, and Shuxuening Injection, have been registered in nearly 20 countries including Singapore, Vietnam, Indonesia, Thailand, Canada, and Australia. The company's main trademark "SHINEWAY" has been registered in the Madrid Agreement and more than 30 countries including the United Kingdom, the United States, South Korea, Indonesia, and Taiwan, Hong Kong and other regions. Products are exported to overseas markets including Southeast Asia, Australia, North America, and Europe. The overseas registration and sales of products have grown from scratch to nearly US$1 million in foreign trade export deliveries in 2019 (including US$530,000 in self-operated exports). An increase of 20% in 2019 compared with 2018. In the first half of 2020, affected by the epidemic, there was a 10% decrease compared with the same period last year. As a modern Chinese medicine enterprise, Shenwei Pharmaceutical Group has been working hard to implement the Chinese medicine going global strategy for the country. In 2014, the company began to develop SLT capsules, a new drug for the treatment of Alzheimer's disease, with Western Sydney University in Australia. The capsules are undergoing new drug registration in Australia. Since 2015, the company has cooperated with Singapore New Drug Company to develop and produce modified